SUNPHARMA.NSSUNPHARMA.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +10.46% | +8.14% | +9.47% | +8.93% | +13.49% |
| Gross Profit Growth | +13.39% | +7.79% | -24.48% | -24.50% | -18.14% |
| EBITDA Growth | +25.15% | +10.46% | +9.92% | +30.62% | +21.37% |
| Operating Income Growth | +16.84% | +10.72% | -50.02% | -54.23% | -46.25% |
| Net Income Growth | +15.04% | -19.01% | -19.64% | +2.56% | +16.03% |
| EPS Growth | +15.02% | -18.92% | -19.63% | +2.36% | +16.03% |
| EPS Diluted Growth | +15.02% | -18.92% | -19.63% | +2.36% | +16.03% |
| Weighted Average Shares Growth | +0.01% | -0.44% | -0.03% | +0.23% | -0.01% |
| Weighted Average Shares Diluted Growth | +0.01% | -0.44% | -0.03% | +0.23% | -0.01% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +15.15% | +0.00% | +18.93% | +0.00% |
| Inventory Growth | +0.00% | -0.50% | +0.00% | +5.10% | +0.00% |
| Asset Growth | +0.00% | +7.77% | +0.00% | +17.69% | +0.00% |
| Book Value per Share Growth | +9.78% | +13.93% | +8.05% | +12.34% | +0.00% |
| Debt Growth | +0.00% | -27.84% | +0.00% | +102.77% | +0.00% |
| R&D Expense Growth | +1.62% | -11.38% | +13.90% | +0.69% | +5.72% |
| SG&A Expenses Growth | +8.00% | +8.15% | +33.55% | +56.04% | +57.39% |